drugset / Trial / NCT00964990
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of JNJ-42160443 in the treatment of moderate to severe neuropathic pain in patients with a diagnosis of postherpetic neuralgia and post-traumatic neuralgia.
Timeline
- Start
- 2009-09
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulranumab | Monoclonal antibody | 1 mg | Subcutaneous |
| Subject | Fulranumab | Monoclonal antibody | 3 mg | Subcutaneous |
| Subject | Fulranumab | Monoclonal antibody | 10 mg | Subcutaneous |